ORYZF News and Press, Oryzon Genomics S.A. From 03/25/22

Virtual Bio-Europe Spring 2022 Kempen Life Sciences Conference Asebio Investor Day MADRID, Spain and CAMBRIDGE, Mass., March 25, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company levera...

In combination with gilteritinib Primary objectives: to assess safety, tolerability and RP2D Secondary objectives: to assess efficacy MADRID, Spain and CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ...

BIO CEO & Investor Conference 2022, New York Epigenetics Symposium – From Genes to Chromatin to Therapeutics BioMed Event 2022, Paris Barclays Global Healthcare Conference, Miami MADRID, Spain and CAMBRIDGE, Mass., Feb. 14, 2022 (GLOBE NEWSWI...

LONDON, UK / ACCESSWIRE / February 10, 2022 / Oryzon is making progress with its two epigenetic drugs, iadademstat for oncology and vafidemstat for CNS indications (both are lysine-specific demethylase 1A, or LSD1, inhibitors). The company's R&D strategy has been to select indications wh...

Oryzon Genomics S.A. press release (OTCPK:ORYZF): GAAP EPS of -$0.04. Cash, cash equivalents and marketable securities totaled $32.5M as of December 31, 2021, compared to $48.6M as of December 31, 2020 For further details see: Oryzon Genomics S.A. GAAP EPS of -$0.04

MADRID, Spain and CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for...

Dr. Ana Limón is a specialist in Oncology with extensive industry experience To coordinate global clinical strategy in oncology from Boston, USA MADRID, Spain and CAMBRIDGE, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, O...

Serbian arm final deployment in PORTICO Study already active in Spain, Bulgaria, Germany and USA MADRID and CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging...

40th Annual J.P. Morgan Healthcare Conference Biotech Showcase 2022 11 th Annual LifeSci Partners Corporate Access Event 2022 H.C. Wainwright Bioconnect Conference BioMed Event 2022 in Paris MADRID, Spain and CAMBRIDGE, Mass., Jan....

Robust efficacy - ORR 78%, of which 62% are CR/CRi 77% of CR/CRi lasting more than 6 months Longest remission beyond 1,000 days, still ongoing Iadademstat and azacitidine combination shows a good safety profile Enrollment in ALICE completed Dosi...